TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03776110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT9906 PR tablet
Description: 40 mg GRT9906 PR tablet oral (minimal release of 80 percent after 480 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT9906 PR tablet
Description: 40 mg GRT9906 PR tablet oral (minimal release of 80 percent after 480 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT9906 PR tablet
Description: 40 mg GRT9906 PR tablet oral (minimal release of 80 percent after 480 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT9906 PR tablet
Description: 40 mg GRT9906 PR tablet oral (minimal release of 80 percent after 480 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet matching 40 mg GRT9906 PR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet matching 40 mg GRT9906 PR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet matching 40 mg GRT9906 PR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet matching 40 mg GRT9906 PR tablet
Study: NCT02873962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: * Bevacizumab will be given intravenously at a pre-determined dosage~* One dose reduction will be allowed for Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: * Bevacizumab will be given intravenously at a pre-determined dosage~* One dose reduction will be allowed for Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: * Bevacizumab will be given intravenously at a pre-determined dosage~* One dose reduction will be allowed for Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: * Nivolumab injection is to be administered as an IV infusion at a pre-determined dosage.~* No dose reductions or escalations will be allowed for Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: * Nivolumab injection is to be administered as an IV infusion at a pre-determined dosage.~* No dose reductions or escalations will be allowed for Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: * Nivolumab injection is to be administered as an IV infusion at a pre-determined dosage.~* No dose reductions or escalations will be allowed for Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: * Rucaparib will be taken orally twice daily on days 1-14 at a pre-determined dosage.~* Up to three dose reductions will be allowed for Rucaparib (depending on cohort).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: * Rucaparib will be taken orally twice daily on days 1-14 at a pre-determined dosage.~* Up to three dose reductions will be allowed for Rucaparib (depending on cohort).
Study: NCT02113098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill, ankle load
Description: The experimental group will perform gait training on a treadmill (Gait Trainer 2®) with added load to the ankle of the non-paretic lower limb, plus physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Description: The control group (active comparator) will perform gait training on a treadmill (Gait Trainer 2®) with physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
Study: NCT02963428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Care
Description: In addition to standard of care, the study participants will also receive:~i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy.
Study: NCT00562302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio-Seal Plug
Description: Deployment of the Bio-Seal plug in needle track
Study: NCT03702075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-administered program
Description: One session was a session supervised by a physical therapist in the Faculty of Health Sciences. This session took place in groups of three or four people. All participants had to follow the physiotherapist instructions about the correct way to do the exercises with the foam roller or ball and nerve mobilizations of upper limbs.The other two weekly sessions were performed at home, following the instructions given by the physiotherapist in session.
Study: NCT03388645

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10^6.3 PFU of RSV A2
Description: Each adult volunteer will receive a single intranasal inoculation of 10\^6.3 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10^7 PFU of RSV A2
Description: Each adult volunteer will receive a single intranasal inoculation of 10\^7 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.
Study: NCT04649788

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided axillary vein access
Description: Venous access is performed through ultrasound-guided axillary vein puncture and Seldinger technique. After venous access is obtained, a guide-wire is advanced through the access needle, and the tip of the guide-wire is positioned in the right cardiac atrium.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cephalic vein access
Description: Venous access is performed through a cephalic vein cutdown approach. After venous access is obtained, a guide-wire is advanced and the tip of the guide-wire is positioned in the right cardiac atrium.
Study: NCT00119691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide
Description: Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
Study: NCT01986361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flurbiprofen
Description: A single flurbiprofen 8.75 mg lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A single placebo lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
Study: NCT03465020

Intervention type: OTHER
Intervention: Observation
Description: Safety and efficacy outcomes of patients on different treatments
Study: NCT01710163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Starting at 300 mg daily, weekly dose will be adjusted according to blood serum level (between 0.5 -0.8mEq/l) according to efficacy and tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Starting at 10 mg daily, dose will be adjusted up to 15 mg daily according to efficacy and tolerability.
Study: NCT00267696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab(Avastin)=10mg/kg on day 1, day 15 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: A regimen consisting of gemcitabine 1000 mg/m2 will be administered on day 1 and day 15 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT02281396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5IU/ml in rabies vaccine （MRC-5 Cell) humans aged 10-20 years old
Description: Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5IU/ml rabies vaccine （MRC-5 Cell) in humans aged 21-60 years old
Description: Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
Study: NCT02394496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1500mg (TBD) O.S. qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1500mg (TBD) O.S. qd
Study: NCT02281396

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 10-20 years old)
Description: Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 21-60 years old)
Description: Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
Study: NCT02394496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: as indicated in the Summary Product Characteristic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: as indicated in the Summary Product Characteristic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Lapatinib
Description: 1500mg (TBD) O.S. qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Lapatinib
Description: 1500mg (TBD) O.S. qd
Study: NCT03666936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social-health care intervention
Description: Cancer survivors enrolled in the study could receive support from the Occupational Therapist and/or from the social care professionist to overcome the difficulties encounter at work or to facilitate work reintegration.
Study: NCT03968003

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: Group A (intervention group) will receive inulin 10 g.Group B will receive placebo of isocaloric maltodextrin. Group C will receive dietary fiber advice aimed to match the recommended fiber intake for age.This study evaluates the changes of gut microbiota composition and diversity, body weight, body fat, SCFAs, plasma amino acids, satiety hormones (PYY and GLP-1), Inflammatory cytokines (IL-1β, TNF-α and IL-6) after 6-month studied period

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Group A (intervention group) will receive inulin 10 g.Group B will receive placebo of isocaloric maltodextrin. Group C will receive dietary fiber advice aimed to match the recommended fiber intake for age.This study evaluates the changes of gut microbiota composition and diversity, body weight, body fat, SCFAs, plasma amino acids, satiety hormones (PYY and GLP-1), Inflammatory cytokines (IL-1β, TNF-α and IL-6) after 6-month studied period

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inulin
Description: Group A (intervention group) will receive inulin 10 g.Group B will receive placebo of isocaloric maltodextrin. Group C will receive dietary fiber advice aimed to match the recommended fiber intake for age.This study evaluates the changes of gut microbiota composition and diversity, body weight, body fat, SCFAs, plasma amino acids, satiety hormones (PYY and GLP-1), Inflammatory cytokines (IL-1β, TNF-α and IL-6) after 6-month studied period
Study: NCT02440984

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colonic biopsies during endoscopy
Description: eligible patients will have physical examination, colonic biopsies during endoscopy and anal manometry with barostat. these investigations are part of the usual healthcare. Colonic biopsies will be used to study intestinal permeability, colonic inflammation and enteric nervous system.
Study: NCT00734110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P.F.C. Sigma Total Knee System
Description: An orthopaedic implant for total knee replacement
Study: NCT04704492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: SM03
Description: Biological: SM03 600 mg or 900 mg intravenous (IV) on week 0,2
Study: NCT03544099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg Intravenous Solution
Study: NCT03748810

Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin 25 mg once daily add on the background OADs for 3 years

Intervention type: DRUG
Intervention: Dapagliflozin
Description: Dapagliflozin 25 mg once daily add on the background OADs for 3 years
Study: NCT00863473

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment with LCP
Study: NCT03186274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Group Session
Description: Participants will review the SPIKES model with a facilitator and then participate in a guided and supported simulated patient encounter utilizing aspects of the SPIKES model, with feedback at the end of the session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CELA Session
Description: Participants will review the SPIKES model on their own and then participate in a simulated patient encounter utilizing the SPIKES model. They will receive feedback following the encounter.
Study: NCT02636231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endostatins
Description: Endostar (Endostatins) is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT is to give GTV 60Gy in 27 fractions.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: IMRT is to give GTV 60Gy in 27 fractions.
Study: NCT03153475

Intervention type: DEVICE
Group type: OTHER
Intervention: ATTUNE Revision Knee System in Revision Total Knee Arthroplasty
Description: Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their existing implants need to be removed and replaced.
Study: NCT01878422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A: FOLFIRI or FOLFOX + Bevacizumab
Description: Arm A: FOLFIRI or FOLFOX + Bevacizumab or Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A: FOLFIRI or FOLFOX + Bevacizumab
Description: Arm A: FOLFIRI or FOLFOX + Bevacizumab or Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B: FOLFIRI or FOLFOX
Description: Arm B: FOLFIRI or FOLFOX or Arm C: FOLFIRI or FOLFOX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B: FOLFIRI or FOLFOX
Description: Arm B: FOLFIRI or FOLFOX or Arm C: FOLFIRI or FOLFOX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm D: FOLFIRI or FOLFOX plus CETUXIMAB
Description: Arm D: FOLFIRI or FOLFOX plus CETUXIMAB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB
Description: Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB
Study: NCT03500731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3/CD19 negative hematopoietic stem cells
Description: Negative selection for CD3/CD19 will be performed on CliniMACS® depletion device and given at time no less than 8 weeks post lung transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Transplantation Conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Transplantation Conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Transplantation Conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Transplantation Conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Transplantation conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Transplantation Conditioning
Study: NCT02964078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab: 200 mg every 3 weeks, 12 doses planned. This is considered the investigational part of the combination. The infusion time is 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2: 8 admissions to hospital, each with 5 doses planned. This is considered the standard part of the combination. The standard interleukin-2 dose is 600,000 international units per kilogram per dose, with a maximum of 66,000,000 (for patients over 110 kg, which is 242 pounds). The dose is usually set at the start of the treatment and not adjusted. The infusion time is 15 minutes.
Study: NCT02944656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Participants in this group will receive 600 mg of gabapentin given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion. Gabapentin is an FDA approved medication that is used to prevent seizures and to treat various forms of chronic and acute pain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this group will receive 600 mg of gelatin capsules that are identical in appearance to gabapentin capsules. The placebo will be given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion.
Study: NCT04631445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Ketogenic diet (KD) will consist of macros: dietary carbohydrates restricted to \< 30 g/day; daily protein intake will be targeted to 1.5 g/kg/day (targeted to ideal body weight).
Study: NCT04205604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluoro Dopa Imaging
Description: Imaging with 18F-Fluoro Dopa PET Imaging
Study: NCT04158739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT
Study: NCT02497963

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Foreskin Graft-Tubularized Incised Plate
Description: TIP Urethroplasty with foreskin graft in primary hypospadias

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tubularized Incised Plate
Description: TIP Urethroplasty without foreskin graft in primary hypospadias
Study: NCT04158739

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab
Description: Given IV
Study: NCT02925182

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Er,Cr:YSGG Laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG Laser
Study: NCT03078296

Intervention type: OTHER
Intervention: survey respondents
Description: all survey participants will be asked to complete a questionnaire
Study: NCT02872974

Intervention type: OTHER
Intervention: GDM
Description: Exposure to GDM during fetal life
Study: NCT01975571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear® Nucleus™ Hybrid L24
Description: The Nucleus Hybrid L24 cochlear implant incorporates an electrode array designed to preserve residual hearing. This has been accomplished by employing a thin, straight, intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The Nucleus Hybrid L24 array has 22 electrodes spread over 16 mm and an anticipated insertion depth of 16 mm. It is slim, with its dimensions ranging from 0.35 x 0.25 mm (at the tip) to 0.55 x 0.4 mm, and designed to minimize lateral wall forces with a stiffened basal section to prevent buckling. The resultant insertion angle is about 280-300° in the scala tympani for the Hybrid L24, as confirmed in temporal bone trials at the Medical University Hannover and the University of Melbourne.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear® Nucleus™ Hybrid L24
Description: The Nucleus Hybrid L24 cochlear implant incorporates an electrode array designed to preserve residual hearing. This has been accomplished by employing a thin, straight, intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The Nucleus Hybrid L24 array has 22 electrodes spread over 16 mm and an anticipated insertion depth of 16 mm. It is slim, with its dimensions ranging from 0.35 x 0.25 mm (at the tip) to 0.55 x 0.4 mm, and designed to minimize lateral wall forces with a stiffened basal section to prevent buckling. The resultant insertion angle is about 280-300° in the scala tympani for the Hybrid L24, as confirmed in temporal bone trials at the Medical University Hannover and the University of Melbourne.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear® Nucleus™ Hybrid S12
Description: The Nucleus Hybrid S12 cochlear implant incorporates an electrode array designed to stimulate the high-frequency, basal region of the cochlea while maintaining useful acoustic hearing in the low-frequency, apical region. This has been accomplished by employing a short, thin, straight intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The electrode array incorporates a collar to prevent over-insertion, or further migration, into the cochlea beyond the point where the basal turn curves into the ascending segment. Thus, the electrode array is placed within the straight segment of the basal turn of the scala tympani via a cochleostomy.
Study: NCT03545295

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block type 2
Description: Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, posterior to the Quadratus Lumborum muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block type 2
Description: Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, posterior to the Quadratus Lumborum muscle